Effect of Dexmedetomidine for Palliative Sedation for Refractory Dyspnoea in Patients with Terminal-Stage Cancer

BACKGROUND: Dyspnoea affects a considerable percentage of patients with terminal-stage cancer, and clinical guidelines recommend palliative sedation for patients with refractory dyspnoea. Midazolam is currently the most commonly used sedative; however, it can cause serious adverse reactions, such as...

Descripción completa

Detalles Bibliográficos
Autores principales: Li, Na, Cui, Meng, Wang, Yumei
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Dove 2023
Materias:
Original Research
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10040164/
https://www.ncbi.nlm.nih.gov/pubmed/36987523
http://dx.doi.org/10.2147/CMAR.S404934

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10040164/
https://www.ncbi.nlm.nih.gov/pubmed/36987523
http://dx.doi.org/10.2147/CMAR.S404934

Ejemplares similares